Compare Amphastar Pharmaceuticals Inc (AMPH) vs First Solar, Inc. (FSLR) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

First Solar (FSLR) trades at $227.83, down 0.29% on the day, with a bearish technical signal despite strong fundamentals. The stock shows robust profitability with a 30.73% net income margin and 18.44% ROE, supported by $2.06B in operating cash flow for 2025. Recent earnings beat expectations in Q1 2026 but missed in prior quarters, while a securities class action lawsuit filed in July 2026 adds near-term uncertainty. Valuation metrics appear reasonable with a P/E of 14.72 and P/S of 4.52.

The outlook is mixed: analyst consensus remains bullish with a $271.55 price target (61.64% buy ratings), but legal risks and technical weakness suggest caution. Upside hinges on execution against 2026 guidance of $1.7B net income, while downside risks include litigation outcomes and competitive pressures in solar manufacturing. Cash flow strength and low debt support resilience amid volatility.